Sleep-Wake Disorders
Alkermes Inc. is active in clinical research focused on narcolepsy and idiopathic hypersomnia, with studies addressing both narcolepsy type 1 and narcolepsy type 2.
- Excessive daytime sleepiness
- Wakefulness regulation
- Idiopathic hypersomnia
- Narcolepsy type 1
- Narcolepsy type 2
The sponsor’s trial portfolio reflects a strong therapeutic interest in disorders that disrupt alertness, sleep continuity, and daytime functioning.
Narcolepsy Type 1 and Narcolepsy Type 2
Clinical activity includes separate research efforts in narcolepsy type 1 and narcolepsy type 2, indicating focused attention on the different clinical presentations of central hypersomnolence disorders.
- Cataplexy-associated narcolepsy
- Sleepiness-related impairment
- Central disorders of hypersomnolence
These studies center on symptoms that affect daily alertness and functional capacity in people living with narcolepsy.
Idiopathic Hypersomnia
Alkermes also funds research in idiopathic hypersomnia, a condition marked by persistent excessive daytime sleepiness and difficulty maintaining wakefulness.
- Daytime sleepiness
- Wakefulness disorders
- Sleep-related impairment
This area of interest aligns with therapeutic development for patients whose symptoms extend beyond nocturnal sleep disturbance to sustained daytime impairment.
Symptom Management in Hypersomnolence Conditions
The sponsor’s clinical research landscape emphasizes treatment of excessive daytime sleepiness across multiple hypersomnolence disorders, including narcolepsy and idiopathic hypersomnia.
- Alertness
- Daytime functioning
- Sleep-wake balance
Research activity spans multiple active sites and countries, supporting investigation of therapies aimed at improving wakefulness-related symptoms in these patient groups.
